BPC-157 vs KPV
Written by the Pure Peptides editorial team
Reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed
Published · Updated · 3 references
BPC-157 and KPV are different molecules: BPC-157 is a 15-residue peptide, and KPV is a three-residue peptide corresponding to residues 11 to 13 of alpha-MSH.
Structure at a glance
BPC-157 · 15 residues
KPV · 3 residues
Letters are one-letter amino acid codes.
Drawn from the product database. Each measure's bars share one scale.
| Property | BPC-157 | KPV |
|---|---|---|
| What it is | A synthetic 15-residue peptide. Described in the originating literature as a partial sequence of a protein reported in human gastric juice.[1] | A synthetic three-residue peptide corresponding to residues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH). |
| How they relate | Different molecules from different parents. BPC-157 is described in the originating literature as a partial sequence of a protein reported in human gastric juice.[1] KPV corresponds to residues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH). | |
| CAS number | 137525-51-0 | 67727-97-3 |
| Molecular formula | C62H98N16O22 | C16H30N4O4 |
| Molecular weight | 1,419.55 g/mol | 342.44 g/mol |
| Sequence | GEPPPGKPADDAGLV | KPV |
| Evidence base | Nearly all published research is preclinical. A 2025 systematic review counted 36 studies within its scope; the one clinical study was a retrospective case series of 12 patients. No randomized controlled trial has been published within that scope. | Its published record is preclinical. No published study has tested KPV in people. |
| Regulatory status | The FDA has not approved BPC-157 for human use. | The FDA has not approved KPV for human use. |
| Compared head-to-head? | No direct comparison found in PubMed (searched October 2026).[2] | |
| Handling difference | Neither contains cysteine, methionine or an aromatic residue. In solution, BPC-157's adjacent aspartates can rearrange. KPV's main instability is ring closure across its first two residues, which cleaves off the third. | |
How BPC-157 and KPV differ
BPC-157 and KPV are different molecules from different parents. BPC-157 is a 15-residue peptide, described in the originating literature as a partial sequence of a protein reported in human gastric juice.[1] That isolated 15-residue form does not occur in nature, and the material used in studies is produced synthetically. KPV is a synthetic three-residue peptide corresponding to residues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), at that hormone's C-terminal end.
Alpha-MSH is amidated at its C-terminus, so the hormone's own three-residue end carries an amide group. KPV has a free acid at that end, which makes it an analog of the hormone's end piece without the amide. BPC-157 and KPV each have a free amine at the N-terminal end and a free acid at the C-terminal end.
A 2025 systematic review found that the BPC-157 evidence base within its scope remains overwhelmingly preclinical.[3] Within that review's scope, the one clinical study was a retrospective case series of 12 patients, and no randomized controlled trial has been published. In the literature reviewed for BPC-157, human safety data are sparse. KPV's published record is preclinical, and no published study has tested KPV in people.
A small number of affiliated laboratories produced much of the foundational animal work on BPC-157. The founding work on KPV came from one laboratory. The literature reviewed for KPV reports no human safety data.
BPC-157 and KPV both contain proline, which restricts rotation of the peptide chain. BPC-157 has four prolines, three of them in a row, and KPV has one, in its second position. In ordinary working conditions, BPC-157 is net anionic, with three acidic side chains against one basic one. KPV is net cationic, with a lysine and no acidic side chain.
Have BPC-157 and KPV been compared directly?
No direct comparison of BPC-157 and KPV was found in a PubMed search run in October 2026.[2] That search covers PubMed only.
Read more on each compound
BPC-157
Frequently Asked Questions
Is BPC-157 the same as KPV?+−
BPC-157 and KPV are different molecules: BPC-157 is a 15-residue peptide, and KPV is a three-residue peptide corresponding to residues 11 to 13 of alpha-MSH. BPC-157 is described in the originating literature as a partial sequence of a protein reported in human gastric juice.
References
- 2
PubMed search, 3 October 2026 (records to 2 October 2026)
1 record; none was a direct comparison of the two compounds.
Exact query (NCBI E-utilities): ("BPC-157"[tiab] OR "BPC 157"[tiab] OR "BPC157"[tiab] OR "body protection compound"[tiab] OR "gastric pentadecapeptide"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("KPV"[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab] OR "alpha-MSH 11-13"[tiab] OR "MSH 11-13"[tiab] OR "Ac-KPV-NH2"[tiab] OR "C-terminal tripeptide"[tiab] OR "carboxyl-terminal tripeptide"[tiab] OR "COOH-terminal tripeptide"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])
View this search on PubMed

Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.
Related comparisons
BPC-157 vs TB-500
BPC-157 is a 15-residue peptide and TB-500 a seven-residue fragment of Thymosin Beta-4: two different molecules.
Read ComparisonBPC-157 vs Thymosin Beta-4
BPC-157 is a 15-residue peptide and Thymosin Beta-4 a 43-residue member of the beta-thymosin family: two different molecules.
Read ComparisonGHK-Cu vs NAD+
GHK-Cu is a copper complex of the tripeptide GHK, and NAD+ is a dinucleotide, not a peptide.
Read Comparison

